Pharmaceutical

Capstan secures $175m Series B funds for CAR-T therapy

Capstan Therapeutics has secured $175m Series B financing to advance its lead in vivo CAR-T candidate, CPTX2309, for autoimmune disorders.

Mar 22, 2024 - 00:00
Capstan secures $175m Series B funds for CAR-T therapy
Capstan Therapeutics has secured $175m Series B financing to advance its lead in vivo CAR-T candidate, CPTX2309, for autoimmune disorders.
Read the original article

Tags:

Previous Article

Bionomics to advance non-SSRI PTSD candidate to Phase III

Next Article

Delivery and manufacturing hurdles remain in the cell and gene therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA panel says Amgen’s Phase III lung cancer KRAS drug data is unreliable

FDA panel says Amgen’s Phase III lung cancer KRAS drug ...

Oct 7, 2023

STAT+: What Amazon Prime’s new One Medical offering reveals about the future of health care

STAT+: What Amazon Prime’s new One Medical offering rev...

Nov 11, 2023

Singapore accepts Everest’s NDA for IgA nephropathy treatment

Singapore accepts Everest’s NDA for IgA nephropathy tre...

Apr 6, 2023